Erythropoietin Use In Patients with AML or Undergoing Allogeneic HSCT Significantly Improves Quality of Life and Reduces Red Blood Cells and Platelets Transfusions without Any Survival Effect.

Mauricette Michallet, Isabelle Jaisson‐Hot, Stéphane Morisset et al.|Blood|2010

Cited by 0